Top Genen­tech re­searcher steps away and Roche turns to the Broad for a star re­place­ment play­er

4 weeks ago
People
R&D

Covid-19 roundup: Charles Riv­er gets slammed by the pan­dem­ic; For­mer Sanofi R&D chief Elias Zer­houni heads a list of can­di­dates for Covid-19 drug czar; Feds try to sort out remde­sivir dis­tri­b­u­tion mess

4 weeks ago
Coronavirus

More than 1,000 clin­i­cal tri­als were stopped by the pan­dem­ic — in­clud­ing dozens in PhI­II

5 weeks ago
Bioregnum
R&D

Covid-19 roundup: Can­cer drug re­search takes a big hit, sur­vey finds; Chaot­ic remde­sivir dis­tri­b­u­tion con­tin­ues to anger doc­tors

5 weeks ago
R&D
Coronavirus

FDA is­n't lift­ing the clin­i­cal hold on Sol­id Bio's Duchenne MD gene ther­a­py just yet — but is there a sil­ver lin­ing?

5 weeks ago
Cell/Gene Tx
Regulatory

Covid-19 roundup: Mod­er­na adds vac­cine ex­perts as PhI­II tri­al looms; Feng Zhang group snags in­stant OK on CRISPR-based test

5 weeks ago
Coronavirus

Flag­ship-backed Evelo Bio­sciences joins Covid-19 hunt with pro­pos­al for bac­te­ria tri­al

5 weeks ago
R&D
Coronavirus

No­var­tis lands cap­ma­tinib ap­proval, giv­ing them a sec­ond po­ten­tial block­buster from In­cyte

5 weeks ago
Pharma
Regulatory

A risky bet on a long-de­layed CAR-T drug now faces a do-or-die dead­line — where any slip can kill a $9 CVR

Last month
R&D
Regulatory

Ab­b­Vie gets the FTC's di­vid­ed bless­ing for its $63B Al­ler­gan buy­out — free­ing Brent Saun­ders to blaze a new path

Last month
People
Deals

Covid-19 roundup: Epi­demi­ol­o­gist cred­it­ed for shap­ing UK pol­i­cy vi­o­lates lock­down mea­sures; Here's Gilead’s glob­al plan for mass man­u­fac­tur­ing remde­sivir

Last month
Coronavirus

Oust­ed BAR­DA chief Rick Bright blasts HHS of­fi­cial for a long record of im­prop­er in­ter­fer­ence that pre­ced­ed the pan­dem­ic

Last month
People
R&D

Alex­ion bags a dis­count biotech buy­out for $1.4B, branch­ing out in new di­rec­tions from its Soliris fran­chise

Last month
Deals

Bat­tling low ex­pec­ta­tions and go­liath ri­vals, Re­gen­eron/Sanofi add pos­i­tive Lib­tayo da­ta in pur­suit of block­buster sta­tus

Last month
R&D
Regulatory

With the pric­ing ball in Gilead’s court, ICER of­fers some pa­ra­me­ters on how it can be played — an­a­lyst sees at least '$1B in the­o­ry'

Last month
Coronavirus

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

Last month
R&D
Coronavirus

Menar­i­ni bags Stem­line and a rare dis­ease drug in $677M buy­out. But will a bet­ter of­fer fol­low?

Last month
Deals

Covid-19 roundup: Catal­ent signs an­oth­er Covid-19 man­u­fac­tur­ing deal; Eli Lil­ly's an­ti­body part­ner grabs $175M+

Last month
Coronavirus

Bris­tol My­ers Squibb gets pri­or­i­ty re­view for AML drug as list of po­ten­tial Cel­gene hits length­ens

Last month
R&D
Regulatory

High-pro­file R&D spe­cial­ist David Leb­wohl jumps to new job as CMO of a pi­o­neer­ing CRISPR play­er; Trou­bled AM­AG Phar­ma­ceu­ti­cals taps Scott My­ers as CEO

Last month
Peer Review

Com­mer­cial strat­e­gy for Gilead­'s Covid-19 drug-to-be remde­sivir re­mains opaque, as chief O'­Day em­pha­sizes re­spon­si­bil­i­ty

Last month
R&D
Pharma

10X: Mod­er­na cre­ates a bil­lion-dose vac­cine pact in a fren­zied race to beat Covid-19 — glob­al­ly

Last month
R&D
Coronavirus

As­traZeneca vaults to the front of the Covid-19 vac­cine race, team­ing up to glob­al­ize Ox­ford can­di­date

Last month
Deals
Coronavirus

Covid-19 roundup: GSK CEO Em­ma Walm­s­ley — some tri­al de­lays, but we’re lim­it­ing the dam­age — so far; Trump plan­ning ‘Warp Speed’ vac­cine plan

Last month
Coronavirus
First page Previous page 1234567 Next page Last page